RT Journal Article
SR Electronic
T1 Inflammasome activation and pulmonary viral loads define two distinct clinical outcomes in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.24.22276878
DO 10.1101/2022.06.24.22276878
A1 Keyla S.G. de Sá
A1 Luana A. Amaral
A1 Camila C.S. Caetano
A1 Amanda Becerra
A1 Sabrina S. Batah
A1 Isadora M. de Oliveira
A1 Letícia S. Lopes
A1 Leticia Almeida
A1 Samuel Oliveira
A1 Danilo Tadao Wada
A1 Marcel Koenigkam-Santos
A1 Ronaldo B. Martins
A1 Roberta R. C. Rosales
A1 Eurico Arruda
A1 Alexandre T Fabro
A1 Dario S. Zamboni
YR 2022
UL http://medrxiv.org/content/early/2022/06/26/2022.06.24.22276878.abstract
AB Inflammasome activation is associated with disease severity in patients who are infected with SARS-CoV-2 and influenza viruses, but the specific cell types involved in inflammasome activation, as well as the balance of inflammasome activation versus viral replication in COVID-19 exacerbation and the induction of patient death, are unknown. In this study, we assessed lung autopsies of 47 COVID-19 and 12 influenza fatal cases and examined the inflammatory profiles and inflammasome activation; additionally, we correlated these factors with clinical and histopathological patient conditions. We observed an overall stronger inflammasome activation in lethal cases of SARS-CoV-2 compared to influenza and found a different profile of inflammasome-activating cells during these diseases. In COVID-19 patients, inflammasome activation is mostly mediated by macrophages and endothelial cells, whereas in influenza, type I and type II pneumocytes contribute more significantly. An analysis of gene expression allowed for the classification of COVID-19 patients into two different clusters. Cluster 1 (n=16 patients) died with higher viral loads and exhibited a reduced inflammatory profile than Cluster 2 (n=31 patients). Illness time, mechanical ventilation time, pulmonary fibrosis, respiratory functions, histopathological status, thrombosis, and inflammasome activation significantly differed between the two clusters. Our data demonstrated two distinct profiles in lethal cases of COVID-19, thus indicating that the balance of viral replication and inflammasome-mediated pulmonary inflammation may lead to different clinical conditions, yet both lead to patient death. An understanding of this process is critical for decisions between immune-mediated or antiviral-mediated therapies for the treatment of critical cases of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, FAPESP grants 2013/08216-2, 2019/11342-6 and 2020/04964-8. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, CNPq grant 303021/2020-9. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, CAPES grant 88887.507253/2020-00.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee of FMRP/USP.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors